connecticut medicaid glp-1 weight loss coverage 2025 Novo Nordisk fights to keep paying for weight-loss drugs People call GLP-1s life-changing. CT

And annual revenue from global obesity drug sales could quadruple to $120 billion by 2030, according to Bloomberg Intelligence

This study was conducted at the Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India, with patient enrolment from February 2021 (first patient in) to July 2021 (last patient out)

Certain conditionsincluding personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2 (MEN2), or severe dehydrationcontraindicate GLP-1 use regardless of dose

This connects it to longevity research involving [Epithalon] and other epigenetic modifiers